Table 5.
n | Baseline | 7 months | 8 months | 9 months | 10 months | 11 months | 12 months | |
Median (min–max) |
Median (min–max) |
Median (min–max) |
Median (min–max) |
Median (min–max) |
Median (min–max) |
Median (min–max) |
||
Visual acuity | 9 | 0.2 (0–1.4) | 0 (0–1.1) | 0 (0–1.1) | 0 (0–1.1) | 0 (0–1.1) | 0 (0–1.1) | 0 (0–1.1) |
p = 0.017 | p = 0.017 | p = 0.017 | p= 0.017 | p= 0.017 | p= 0.017 | |||
Cell | 9 | 0.5 (0–4) | 0 (0–1) | 0 (0–1) | 0 (0–0.5) | 0 (0–0) | 0 (0–0.5) | 0 (0–0.5) |
p = 0.034 | p = 0.008 | p = 0.021 | p= 0.008 | p= 0.014 | p= 0.008 | |||
IOP | 9 | 28 (14–44) | 14 (8–17) | 12 (6–18) | 12 (9–17) | 15 (1–24) | 14 (1–24) | 12 (1–17) |
p = 0.013 | p = 0.011 | p = 0.008 | p= 0.021 | p= 0.018 | p= 0.012 | |||
Antiglaucoma drug | 9 | 3 (1–6) | 1 (0–2) | 1 (0–2) | 1 (0–2) | 1 (0–2) | 0 (0–2) | 0 (0–2) |
p = 0.011 | p = 0.011 | p = 0.011 | p= 0.012 | p= 0.007 | p= 0.007 | |||
Steroid | 9 | 4 (2–16) | 0 (0–6) | 0 (0–4) | 0 (0–4) | 0 (0–4) | 0 (0–4) | 0 (0–4) |
p = 0.024 | p = 0.012 | p = 0.012 | p= 0.011 | p= 0.016 | p= 0.011 | |||
KPs present | 9 | 10 (90.9%) | 1 (11.11%) | 0 | 1 (11.11%) | 2 (22.22%) | 2 (22.22%) | 2 (22.22%) |
p = 0.016 | NA | p = 0.016 | p= 0.031 | p= 0.031 | p= 0.031 |
Wilcoxon Signed-rank test.
McNemar test.
Significant (p<0.05).
IOP, intraocular pressure; KPs, keratic precipitates.